These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 17498515)
1. Drug treatment of the overweight patient. Bray GA; Ryan DH Gastroenterology; 2007 May; 132(6):2239-52. PubMed ID: 17498515 [TBL] [Abstract][Full Text] [Related]
2. Long-term pharmacotherapy for obesity and overweight. Padwal R; Li SK; Lau DC Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004 [TBL] [Abstract][Full Text] [Related]
3. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116 [TBL] [Abstract][Full Text] [Related]
4. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Rubio MA; Gargallo M; Isabel Millán A; Moreno B Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331 [TBL] [Abstract][Full Text] [Related]
5. Long-term pharmacotherapy for obesity and overweight. Padwal R; Li SK; Lau DC Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy in the treatment of obesity]. Hamann A MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392 [TBL] [Abstract][Full Text] [Related]
8. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Padwal RS; Majumdar SR Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Halford JC Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapeutic options for overweight adolescents. Dunican KC; Desilets AR; Montalbano JK Ann Pharmacother; 2007 Sep; 41(9):1445-55. PubMed ID: 17652127 [TBL] [Abstract][Full Text] [Related]
11. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Madsbad S Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255 [TBL] [Abstract][Full Text] [Related]
12. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Johansson K; Sundström J; Neovius K; Rössner S; Neovius M Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of obesity. Mancini MC; Halpern A Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304 [TBL] [Abstract][Full Text] [Related]
14. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Padwal R; Li SK; Lau DC Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638 [TBL] [Abstract][Full Text] [Related]
15. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Caterson ID; Finer N Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662 [TBL] [Abstract][Full Text] [Related]
17. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Zieba R Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763 [TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
20. Time series analyses of the effect of FDA communications on use of prescription weight loss medications. Block JP; Choudhry NK; Carpenter DP; Fischer MA; Brennan TA; Tong AY; Matlin OS; Shrank WH Obesity (Silver Spring); 2014 Mar; 22(3):943-9. PubMed ID: 23929685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]